Imdelltra received accelerated approval from the U.S. Food and Drug Administration in 2024 for extensive-stage small-cell lung cancer, followed by traditional approval in 2025. The drug generated $513 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results